Comprehensive profiles for 105+ peptides — dosing protocols, mechanisms of action, clinical research, and safety data.
105
Peptides
9
Categories
15 peptides match your filters
5-amino-1-methylquinolinium
A selective NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular energy metabolism. Not technically a peptide but a small molecule research compound. Mouse studies showed 30%+ decrease in adipocyte size.
Anti-Obesity Drug 9604
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Semaglutide + Cagrilintide
Investigational combination therapy demonstrating 22.7% body weight reduction at 68 weeks in Phase 3 trials, outperforming semaglutide monotherapy.
AM833
Long-acting amylin analog for obesity treatment operating through distinct pathways compared to GLP-1 agonists. Phase 3: 11.8% weight loss (monotherapy); 20.4% (CagriSema combination).
Trulicity
An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration (~5 day half-life).
Byetta
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. 53% homology with human GLP-1.
Frag 176-191
The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.
Victoza
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing. 97% homology to native GLP-1.
LY3502970
An oral non-peptide GLP-1 receptor agonist. First oral GLP-1 agonist not requiring food restrictions.
LY3437943
A triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.
Ozempic
A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
Rybelsus
The first oral GLP-1 receptor agonist FDA approved, using SNAC absorption enhancer. Achieves 80% bioavailability of subcutaneous injection.
Imcivree
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
BI 456906
A dual GLP-1/glucagon receptor agonist being developed for obesity and metabolic dysfunction-associated fatty liver disease (MASH). Phase 2 showed 83% MASH resolution vs 18% placebo.
Mounjaro
A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.